Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Clinical trial DA1241_NASH_IIa is a multicenter, randomized, double‐blind,placebo‐controlled, parallel‐arm, Phase 2a clinical trial to evaluate the efficacy andsafety of DA‐1241 in subjects with presumed NAFLD.Part 1 of this clinical trial intends to explore the efficacy of DA‐1241 in subjects withNASH after administration of oral DA‐1241 at varying doses or identical placebo in 3treatment groups for 16 weeks/112 days.Part 2 intends to explore the efficacy of DA‐1241 in subjects with NASH afteradministration of oral DA‐1241 in combination with sitagliptin versus an identicalplacebo for 16 weeks/112 days.